17 unchanged sentences
immediately, $1.0 million on July 13, 2022, and $500,000 on July 13, 2023.
+Added: On April 29, 2022, the Company agreed to an amendment to Section
+Added: 3.1 of the Global Agreement, pursuant to which the Company agreed to pay Clarus $1,250,000 in May 2022, with no additional payments required
No future royalties are owing from either party.
−Removed: 2021, the Court dismissed with prejudice Lipocine’s claims and Clarus’ counterclaims.
+Added: On July 15, 2021, the Court dismissed with prejudice Lipocine’s claims
+Added: and Clarus’ counterclaims.
November 14, 2019, we and certain of our officers were named as defendants in a purported shareholder class action lawsuit, Solomon
15 unchanged sentences
dismiss on October 22, 2020.
−Removed: A hearing on the motion to dismiss has been scheduled for January 12, 2022.
−Removed: We intend to vigorously defend
−Removed: ourselves against these allegations and have not recorded a liability related to this shareholder class action lawsuit as the outcome
−Removed: is not probable nor can an estimate be made of loss, if any.
+Added: A hearing on the motion to dismiss occurred on January 12, 2022.
+Added: We intend to vigorously defend ourselves
+Added: against these allegations and have not recorded a liability related to this shareholder class action lawsuit as the outcome is not probable
+Added: nor can an estimate be made of loss, if any.
March 13, 2020, we filed U.S.
patent application serial number 16/818,779 (“the Lipocine ‘779 Application”) with the
−Removed: On October 16 and November 3, 2020, we filed suggestions for interference with the USPTO requesting that a patent interference
−Removed: be declared between the Lipocine ‘779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics, Inc.
+Added: United States Patent and Trademark Office (“USPTO”).
+Added: On October 16 and November 3, 2020, we filed suggestions for interference
+Added: with the USPTO requesting that a patent interference be declared between the Lipocine ‘779 Application and US patent application
+Added: serial number 16/656,178 to Clarus Therapeutics, Inc.
(“the Clarus ‘178 Application”).
−Removed: Pursuant to our request, the Patent Trial and Appeal Board (“PTAB”) at
−Removed: the USPTO declared the interference on January 4, 2021 to ultimately determine, as between us and Clarus, who is entitled to the claimed
−Removed: subject matter.
−Removed: The interference number is 106,128, and we were initially declared Senior Party.
−Removed: A conference call with the PTAB was
−Removed: held on January 25, 2021 to discuss proposed motions.
−Removed: On February 1, 2021, the PTAB issued an order authorizing certain motions and setting
−Removed: the schedule for the preliminary motions phase.
−Removed: On July 13, 2021, we entered into the Global Agreement with Clarus to resolve interference
+Added: Pursuant to our request, the
+Added: Patent Trial and Appeal Board (“PTAB”) at the USPTO declared the interference on January 4, 2021, to ultimately determine,
+Added: as between us and Clarus, who is entitled to the claimed subject matter.
+Added: The interference number is 106,128, and we were initially declared
+Added: Senior Party.
+Added: A conference call with the PTAB was held on January 25, 2021, to discuss proposed motions.
+Added: On February 1, 2021, the PTAB
+Added: issued an order authorizing certain motions and setting the schedule for the preliminary motions phase.
+Added: On July 13, 2021, we entered
+Added: into the Global Agreement with Clarus to resolve interference No.
106,128 among other items.
−Removed: On July 26, 2021, the PTAB granted our request for adverse judgment in interference No.
−Removed: 106,128 in accordance
−Removed: with the Global Agreement.
+Added: On July 26, 2021, the PTAB granted our request
+Added: for adverse judgment in interference No.
+Added: 106,128 in accordance with the Global Agreement.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.